Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 16:8:748449.
doi: 10.3389/fmolb.2021.748449. eCollection 2021.

Role of BET Proteins in Inflammation and CNS Diseases

Lei Liu  1 , Changjun Yang  1 , Eduardo Candelario-Jalil  1
Affiliations
Review

Role of BET Proteins in Inflammation and CNS Diseases

Lei Liu et al. Front Mol Biosci. .

Abstract

Bromodomain and extra-terminal domain (BET) proteins consist of four mammalian members (BRD2, BRD3, BRD4, and BRDT), which play a pivotal role in the transcriptional regulation of the inflammatory response. Dysregulated inflammation is a key pathological process in various CNS disorders through multiple mechanisms, including NF-κB and Nrf2 pathways, two well-known master regulators of inflammation. A better mechanistic understanding of the BET proteins' role in regulating the inflammatory process is of great significance since it could reveal novel therapeutic targets to reduce neuroinflammation associated with many CNS diseases. In this minireview, we first outline the structural features of BET proteins and summarize genetic and pharmacological approaches for BET inhibition, including novel strategies using proteolysis-targeting chimeras (PROTACs). We emphasize in vitro and in vivo evidence of the interplay between BET proteins and NF-κB and Nrf2 signaling pathways. Finally, we summarize recent studies showing that BET proteins are essential regulators of inflammation and neuropathology in various CNS diseases.

Keywords: Alzheimer’s disease; multiple sclerosis; neuroinflammation; neurological diseases; proteolysis-targeting chimera; seizure; spinal cord injury; stroke.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Human BET family structural domains and mechanisms of inhibition. (A) Structural domains of BET proteins. All BET proteins share two tandem N-terminal bromodomains (BD1 and BD2) and an extra-terminal (ET) domain. In addition, Brd4 and BrdT contain a unique C-terminal domain (CTD). The numbers refer to the amino acid boundaries of each domain for the human BET proteins. The alignment of amino acid (aa) sequences is from the public protein sequence database, GenPept, NCBI Reference Sequence: Brd2, NP_005095.1; Brd3, NP_031397.1; Brd4, NP_490,597.1; BrdT, NP_001229734.2. (B) To date, all reported BET inhibitors (BETis) target BDs on BET proteins. (C) BET PROTAC mechanism. The E1 enzyme activates ubiquitin (Ub) and initiates its transfer to a target substrate through the E1-E2-E3 cascade. Then, the target substrate tagged by ubiquitin is degraded by the proteasome. Without BET PROTAC, BET protein is not recognizable for the ubiquitination process. BET PROTAC molecules can bind the target BET protein and the E3 ubiquitin ligase together, and such binding ubiquitinates the target protein, making it available for subsequent proteasomal degradation.
See this image and copyright information in PMC

References

    1. An Q. d., Li Y. y., Zhang H. x., Lu J., Yu X. d., Lin Q., et al. (2018). Inhibition of Bromodomain‐containing Protein 4 Ameliorates Oxidative Stress-Mediated Apoptosis and Cartilage Matrix Degeneration through Activation of NF‐E2-Related Factor 2‐heme Oxygenase‐1 Signaling in Rat Chondrocytes. J. Cel Biochem 119, 7719–7728. 10.1002/jcb.27122 - DOI - PubMed
    1. Bandukwala H. S., Gagnon J., Togher S., Greenbaum J. A., Lamperti E. D., Parr N. J., et al. (2012). Selective Inhibition of CD4+ T-Cell Cytokine Production and Autoimmunity by BET Protein and C-Myc Inhibitors. Proc. Natl. Acad. Sci. 109, 14532–14537. 10.1073/pnas.1212264109 - DOI - PMC - PubMed
    1. Bao Y., Wu X., Chen J., Hu X., Zeng F., Cheng J., et al. (2017). Brd4 Modulates the Innate Immune Response through Mnk2-eIF4E Pathway-dependent Translational Control of IκBα. Proc. Natl. Acad. Sci. USA 114, E3993–E4001. 10.1073/pnas.1700109114 - DOI - PMC - PubMed
    1. Barrett E., Brothers S., Wahlestedt C., Beurel E. (2014). I-BET151 Selectively Regulates IL-6 Production. Biochim. Biophys. Acta (Bba) - Mol. Basis Dis. 1842, 1549–1555. 10.1016/j.bbadis.2014.05.013 - DOI - PMC - PubMed
    1. Belkina A. C., Denis G. V. (2012). BET Domain Co-regulators in Obesity, Inflammation and Cancer. Nat. Rev. Cancer 12, 465–477. 10.1038/nrc3256 - DOI - PMC - PubMed